Abstract
Purpose: This study aimed to explore clinical-pathological shrinkage modes oriented toward breast-conserving surgery (BCS) after neoadjuvant therapy (NAT) using three-dimensional (3D) MRI and pathology reconstruction. Methods: 104 breast cancer patients were prospectively studied between 2014 and 2018. 3D MRI and pathology models were reconstructed to assess residual tumor patterns. Shrinkage modes were categorized into clinical pathological-concentric (CP-CSM) and non-concentric (CP-NCSM). Results: 3D MRI reconstruction predicted shrinkage modes with 93.3% accuracy. Independent predictors included primary tumor stage, malignant calcification, molecular subtypes, and nodal down-staging. Patients with CP-CSM showed significantly better survival outcomes. Conclusion: 3D MRI reconstruction and the developed nomogram provide a reliable tool for guiding individualized BCS selection.
Introduction
Neoadjuvant therapy (NAT) is increasingly used to downstage breast cancer, potentially converting patients from mastectomy candidates to breast-conserving surgery (BCS) candidates. However, the safety of BCS depends heavily on the pattern of tumor regression. While "concentric" shrinkage (CP-CSM) allows for clear surgical margins, "non-concentric" shrinkage (CP-NCSM)—characterized by scattered residual "islands" of cancer—poses a high risk of local recurrence. Traditional 2D imaging often fails to accurately map these complex 3D residual volumes. This study utilizes 3D MRI and pathological reconstruction to better define these shrinkage modes and predict surgical outcomes.
Methods and Patient Cohort
The study prospectively enrolled 104 female patients at the Shandong Cancer Hospital Breast Cancer Center. The cohort's baseline characteristics, including molecular subtypes and clinical stages, are summarized in the table below.
3D Reconstruction and Classification
Patients underwent MRI before and after NAT. 3D-DOCTOR software was used to build volumetric models from MRI data. Post-surgery, residual tumors were analyzed via sub-serial sectioning (5mm slices) to create a "gold standard" 3D pathology model.
Shrinkage was classified into:
- CP-CSM (Concentric): Residual tumor diameter <50% of the primary tumor and ≤2cm.
- CP-NCSM (Non-concentric): All other patterns, including multinodular or diffuse residual lesions.
Results
Predictive Accuracy of 3D MRI
The 3D MRI reconstruction demonstrated high performance in predicting clinical-pathological shrinkage modes, achieving an accuracy of 93.3%, sensitivity of 97.0%, and specificity of 86.5% (Kappa = 0.850).
Independent Predictors and Nomogram
Multivariate analysis identified four independent predictors of shrinkage mode:
- Primary tumor stage (OR=2.059)
- Mammographic malignant calcification (OR=3.424)
- Molecular subtype (OR=0.530)
- Nodal down-staging after NAT (OR=0.183)
A nomogram incorporating these factors achieved an Area Under the Curve (AUC) of 0.833, indicating strong predictive power for identifying candidates suitable for BCS.
Survival Outcomes
With a median follow-up of 77 months, the CP-CSM group exhibited a significantly lower recurrence/metastasis rate (7.1%) compared to the CP-NCSM group (29.4%, p=0.002). Both overall survival (OS) and disease-free survival (DFS) were significantly improved in the CP-CSM group.
Discussion
The integration of 3D MRI reconstruction provides a more nuanced understanding of tumor response to NAT than traditional diameter-based measurements. By identifying patients likely to undergo concentric shrinkage, surgeons can more confidently recommend BCS even in cases that might have previously been deemed high-risk.
While the results are promising, the study's single-center nature and the technical complexity of 3D pathological reconstruction are limitations. Future multi-center trials are necessary to validate the nomogram for broader clinical application. This approach represents a significant step toward personalized surgical planning in breast cancer treatment.
Summary updated